This company listing is no longer active
Eisai Toekomstige groei
Future criteriumcontroles 4/6
Belangrijke informatie
27.7%
Groei van de winst
27.5%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 24.5% |
Inkomstengroei | 9.7% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Good |
Laatst bijgewerkt | n/a |
Recente toekomstige groei-updates
Recent updates
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
3/31/2025 | 866,980 | 78,690 | 77,512 | 104,824 | 12 |
3/31/2024 | 783,396 | 53,074 | 62,266 | 95,417 | 13 |
3/31/2023 | 744,420 | 57,359 | 63,939 | 104,293 | 13 |
9/30/2022 | 752,500 | 32,233 | -8,913 | 30,329 | N/A |
6/30/2022 | 741,594 | 32,690 | 94,326 | 135,806 | N/A |
3/31/2022 | 756,226 | 47,954 | 77,123 | 117,590 | N/A |
12/31/2021 | 712,935 | 57,311 | 85,128 | 124,927 | N/A |
9/30/2021 | 691,250 | 62,508 | 80,215 | 123,618 | N/A |
6/30/2021 | 679,253 | 59,855 | 8,589 | 49,533 | N/A |
3/31/2021 | 645,942 | 42,119 | 35,709 | 73,853 | N/A |
12/31/2020 | 707,888 | 93,682 | 52,352 | 95,670 | N/A |
9/30/2020 | 713,400 | 120,571 | 77,080 | 112,990 | N/A |
6/30/2020 | 707,203 | 124,523 | 81,101 | 116,904 | N/A |
3/31/2020 | 695,621 | 121,767 | 52,556 | 102,782 | N/A |
12/31/2019 | 661,646 | 96,659 | 21,665 | 72,461 | N/A |
9/30/2019 | 631,974 | 57,725 | 12,273 | 62,240 | N/A |
6/30/2019 | 643,531 | 72,747 | 38,725 | 87,299 | N/A |
3/31/2019 | 642,834 | 63,386 | 76,092 | 103,714 | N/A |
12/31/2018 | 627,367 | 63,714 | 151,104 | 171,330 | N/A |
9/30/2018 | 625,106 | 65,679 | 167,298 | 186,973 | N/A |
6/30/2018 | 611,499 | 54,347 | 145,007 | 165,689 | N/A |
3/31/2018 | 600,054 | 51,845 | 124,916 | 149,649 | N/A |
12/31/2017 | 569,814 | 29,048 | 42,233 | 72,041 | N/A |
9/30/2017 | 554,276 | 30,269 | 33,537 | 61,644 | N/A |
6/30/2017 | 544,027 | 29,425 | 49,931 | 76,929 | N/A |
3/31/2017 | 539,097 | 39,358 | 55,850 | 75,851 | N/A |
12/31/2016 | 530,696 | 55,031 | 62,558 | 76,725 | N/A |
9/30/2016 | 542,313 | 71,812 | 66,612 | 78,627 | N/A |
6/30/2016 | 545,602 | 69,227 | N/A | 69,710 | N/A |
3/31/2016 | 547,922 | 54,933 | N/A | 95,617 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: ESAL.Y's forecast earnings growth (27.7% per year) is above the savings rate (2%).
Winst versus markt: ESAL.Y's earnings (27.7% per year) are forecast to grow faster than the US market (14% per year).
Hoge groeiwinsten: ESAL.Y's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: ESAL.Y's revenue (9.7% per year) is forecast to grow faster than the US market (7% per year).
Hoge groei-inkomsten: ESAL.Y's revenue (9.7% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if ESAL.Y's Return on Equity is forecast to be high in 3 years time